Cellomics offers customers expanded HCS training
Advanced courses focus on specific research and therapeutic applications
PITTSBURGH, Sept. 14, 2006—Cellomics, the creator of and world leader in high content screening (HCS) and a unit of Fisher Biosciences, has expanded its continuing education curriculum with the introduction of advanced courses in HCS applications. These courses will offer customers training for specific uses in biology research and therapeutics, including such fields as oncology, neurobiology and toxicology.
Two classes are scheduled for the fall. HCS 202, to be offered Oct. 25-26, will cover high-content screening applications for cancer research in cell-cycle regulation, apoptosis and necrosis as well as angiogenesis. The second course, HCS 201, will be held Dec. 5-6, and will teach participants HCS techniques in toxicology focused on cytotoxicity, genotoxicity as well as novel assays for a broad range of other toxicity indicators. Additional classes, to be scheduled in the spring, will offer customers training in applications for neurobiology as well as signaling and other areas of cancer research.
“HCS continues to grow from a new technology to an accepted and applied form of cell-based assay screening in the pharmaceutical, biotech and academic arenas,” said Dan Calvo, president and chief executive officer of Cellomics. “The HCS 200 seriesof courses is an opportunity for scientists to expand their high content analysis knowledge and become power users within their therapeutic discipline.”
The HCS 200 series is designed for established users who seek more in-depth training and want to maximize HCS for their therapeutic area, as well as advanced users who are looking for new ideas about specific assays that can be automated using HCS. (HCS 101 is not a prerequisite for these classes, but it is strongly recommended.)
The advanced courses build on the highly successful HCS 101 class, which Cellomics has offered since 2003, providing customers with an introduction to high content screening. More than 200 customers have completed the introductory course.
All courses are held at Cellomics’ dedicated training facility in Pittsburgh, providing participants with hands-on experience with Cellomics automated imaging systems and assays. Registration and general information on the HCS 200 courses are available on the Cellomics Web site at www.cellomics.com or by calling Cellomics at 800-432-4091.
Cellomics, a business unit within the Fisher Biosciences group, provides complete systems for High Content Screening (HCS) and Analysis (HCA) to drug discovery and systems biology researchers. The Cellomics platform includes automated imaging instrumentation (ArrayScan® and KineticScan® HCS Readers and the cellWoRxTM High Content Cell Analysis System), BioApplication image analysis software, High Content Informatics (HCiTM ), and HitKit® HCS Reagent Kits, fully integrated to improve the quality and productivity of cell-based assays. Cellomics’ proprietary platforms are in use at multiple sites within the top 15 pharmaceutical companies, as well as leading biotechnology companies and academic centers throughout the world. For more information about Cellomics-brand products and services, please visit www.cellomics.com or call 412-770-2200.
About Fisher Biosciences
Fisher Biosciences, a unit of Fisher Scientific International Inc., manufactures and supplies a wide range of products and services across the general-chemistry and life-sciences arenas. From fine and high-purity chemicals, clinical diagnostics, proprietary protein-research and cell-culture products, and sterile-liquid-handling systems, to innovative RNA-interference technology and high content screening, Fisher Biosciences serves scientific-research, healthcare, drug-discovery, and general industrial customers around the world. Additional information about Fisher Biosciences is available online at www.fisherbiosci.com.
- Contact Information
- Product Service and Technical Support
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.